Optimal treatment for metastatic bladder cancer

Estrella M. Carballido, Jonathan E. Rosenberg

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine-cisplatin and methotrexate-vinblastine-doxorubicin-cisplatin, are the standard first-line therapies. Second-line therapies have modest activity and no significant improvement in patient outcomes. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefit to date. Modulating host immune response to cancer-associated antigens appears promising, with multiple new therapeutic approaches being pursued. Next-generation sequencing of invasive urothelial carcinoma has provided insights into the biology of this disease and potential actionable targets. Alterations in the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway represent potential therapeutic targets in advanced disease, and novel agents are in development. Recent data from the Cancer Genome Atlas Research Network bladder cancer cohort and other efforts suggest that mutations in chromatin-regulatory genes are very common in invasive bladder tumors, and are more frequent than in other studied tumors. The discovery of new genomic alterations challenges drug development to change the course of this disease.

Original languageEnglish (US)
Article number404
JournalCurrent Oncology Reports
Volume16
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Urinary Bladder Neoplasms
Cisplatin
gemcitabine
Phosphatidylinositol 3-Kinase
Therapeutics
Neoplasms
Proto-Oncogene Proteins c-akt
Vinblastine
Atlases
Receptor Protein-Tyrosine Kinases
Sirolimus
Regulator Genes
Combination Drug Therapy
Methotrexate
Doxorubicin
Chromatin
Genome
Carcinoma
Antigens
Mutation

Keywords

  • Immunotherapeutics
  • Metastatic bladder cancer
  • Molecularmarkers
  • Targeted therapies
  • Urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Optimal treatment for metastatic bladder cancer. / Carballido, Estrella M.; Rosenberg, Jonathan E.

In: Current Oncology Reports, Vol. 16, No. 9, 404, 2014.

Research output: Contribution to journalArticle

Carballido, Estrella M. ; Rosenberg, Jonathan E. / Optimal treatment for metastatic bladder cancer. In: Current Oncology Reports. 2014 ; Vol. 16, No. 9.
@article{7fca7380eab14ede9c1a8832676d1d0c,
title = "Optimal treatment for metastatic bladder cancer",
abstract = "Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine-cisplatin and methotrexate-vinblastine-doxorubicin-cisplatin, are the standard first-line therapies. Second-line therapies have modest activity and no significant improvement in patient outcomes. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefit to date. Modulating host immune response to cancer-associated antigens appears promising, with multiple new therapeutic approaches being pursued. Next-generation sequencing of invasive urothelial carcinoma has provided insights into the biology of this disease and potential actionable targets. Alterations in the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway represent potential therapeutic targets in advanced disease, and novel agents are in development. Recent data from the Cancer Genome Atlas Research Network bladder cancer cohort and other efforts suggest that mutations in chromatin-regulatory genes are very common in invasive bladder tumors, and are more frequent than in other studied tumors. The discovery of new genomic alterations challenges drug development to change the course of this disease.",
keywords = "Immunotherapeutics, Metastatic bladder cancer, Molecularmarkers, Targeted therapies, Urothelial carcinoma",
author = "Carballido, {Estrella M.} and Rosenberg, {Jonathan E.}",
year = "2014",
doi = "10.1007/s11912-014-0404-2",
language = "English (US)",
volume = "16",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "9",

}

TY - JOUR

T1 - Optimal treatment for metastatic bladder cancer

AU - Carballido, Estrella M.

AU - Rosenberg, Jonathan E.

PY - 2014

Y1 - 2014

N2 - Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine-cisplatin and methotrexate-vinblastine-doxorubicin-cisplatin, are the standard first-line therapies. Second-line therapies have modest activity and no significant improvement in patient outcomes. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefit to date. Modulating host immune response to cancer-associated antigens appears promising, with multiple new therapeutic approaches being pursued. Next-generation sequencing of invasive urothelial carcinoma has provided insights into the biology of this disease and potential actionable targets. Alterations in the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway represent potential therapeutic targets in advanced disease, and novel agents are in development. Recent data from the Cancer Genome Atlas Research Network bladder cancer cohort and other efforts suggest that mutations in chromatin-regulatory genes are very common in invasive bladder tumors, and are more frequent than in other studied tumors. The discovery of new genomic alterations challenges drug development to change the course of this disease.

AB - Metastatic bladder cancer is a lethal disease. Cisplatin-based chemotherapy, including the combination regimens gemcitabine-cisplatin and methotrexate-vinblastine-doxorubicin-cisplatin, are the standard first-line therapies. Second-line therapies have modest activity and no significant improvement in patient outcomes. Agents targeting growth, survival, and proliferation pathways have been added to cytotoxic therapy with limited added benefit to date. Modulating host immune response to cancer-associated antigens appears promising, with multiple new therapeutic approaches being pursued. Next-generation sequencing of invasive urothelial carcinoma has provided insights into the biology of this disease and potential actionable targets. Alterations in the receptor tyrosine kinase/Ras pathway and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway represent potential therapeutic targets in advanced disease, and novel agents are in development. Recent data from the Cancer Genome Atlas Research Network bladder cancer cohort and other efforts suggest that mutations in chromatin-regulatory genes are very common in invasive bladder tumors, and are more frequent than in other studied tumors. The discovery of new genomic alterations challenges drug development to change the course of this disease.

KW - Immunotherapeutics

KW - Metastatic bladder cancer

KW - Molecularmarkers

KW - Targeted therapies

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84904525746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904525746&partnerID=8YFLogxK

U2 - 10.1007/s11912-014-0404-2

DO - 10.1007/s11912-014-0404-2

M3 - Article

C2 - 25056737

AN - SCOPUS:84904525746

VL - 16

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 9

M1 - 404

ER -